» Articles » PMID: 25556561

Opalescence in Monoclonal Antibody Solutions and Its Correlation with Intermolecular Interactions in Dilute and Concentrated Solutions

Overview
Journal J Pharm Sci
Publisher Elsevier
Specialties Pharmacology
Pharmacy
Date 2015 Jan 6
PMID 25556561
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

Opalescence indicates physical instability of a formulation because of the presence of aggregates or liquid-liquid phase separation in solution and has been reported for monoclonal antibody (mAb) formulations. Increased solution opalescence can be attributed to attractive protein-protein interactions (PPIs). Techniques including light scattering, AUC, or membrane osmometry are routinely employed to measure PPIs in dilute solutions, whereas opalescence is seen at relatively higher concentrations, where both long- and short-range forces contribute to overall PPIs. The mAb molecule studied here shows a unique property of high opalescence because of liquid-liquid phase separation. In this study, opalescence measurements are correlated to PPIs measured in diluted and concentrated solutions using light scattering (kD ) and high-frequency rheology (G'), respectively. Charges on the molecules were calculated using zeta potential measurements. Results indicate that high opalescence and phase separation are a result of the attractive interactions in solution; however, the presence of attractive interactions do not always imply phase separation. Temperature dependence of opalescence suggests that thermodynamic contribution to opalescence is significant and Tcloud can be utilized as a potential tool to assess attractive interactions in solution.

Citing Articles

Assessing the Manufacturability and Critical Quality Attribute Profiles of Anti-IL-8 Immunoglobulin G Mutant Variants.

Armstrong G, Burley G, Lewis W, Rattray Z Mol Pharm. 2024; 21(12):6423-6432.

PMID: 39509699 PMC: 11615950. DOI: 10.1021/acs.molpharmaceut.4c01010.


A scaling relationship between thermodynamic and hydrodynamic interactions in protein solutions.

Kingsbury J, Starr C, Gokarn Y Biophys J. 2024; 123(22):3871-3883.

PMID: 39360382 PMC: 11617628. DOI: 10.1016/j.bpj.2024.09.032.


Stability of Protein Pharmaceuticals: Recent Advances.

Manning M, Holcomb R, Payne R, Stillahn J, Connolly B, Katayama D Pharm Res. 2024; 41(7):1301-1367.

PMID: 38937372 DOI: 10.1007/s11095-024-03726-x.


The role of acidification of the medium on the erythrocyte agglutinating and adsorbing properties of blood group-specific monoclonal antibodies.

Delevsky Y, Zinchenko O Korean J Transplant. 2023; 37(3):189-196.

PMID: 37751966 PMC: 10583970. DOI: 10.4285/kjt.23.0033.


A systematic review of commercial high concentration antibody drug products approved in the US: formulation composition, dosage form design and primary packaging considerations.

Ghosh I, Gutka H, Krause M, Clemens R, Kashi R MAbs. 2023; 15(1):2205540.

PMID: 37243580 PMC: 10228404. DOI: 10.1080/19420862.2023.2205540.